Skip to main content

C4 Therapeutics, Inc.

CCCC
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001662579

No open-market purchases or sales by C4 Therapeutics, Inc. insiders were filed in the last 90 days; 147 institutions reported holding it in 13F filings for Q2 2026, worth $547.6M in total; no superinvestor holds it.

13F holders, Q1 2026

Institutional positions in C4 Therapeutics, Inc. as of Mar 31, 2026. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works

Institutional holders
123
+23 vs. Q4 2025
Shares held
84.5M
+9.04M (+12.0%) vs. Q4 2025
Total value
$221.3M
+$77.2M (+53.6%) vs. Q4 2025
New holders
34
41 more added
Sold out
11
30 more reduced

1 institution that held it in Q4 2025 haven't filed for Q1 2026 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.

Compare with Q4 2025: new holders, sold out and not filed yet

Holders and value by quarter

Institutions reporting CCCC on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.

Institutional holdersQ1 2026: 123 institutions
Q1 2021: 83 institutionsQ2 2021: 107 institutionsQ3 2021: 113 institutionsQ4 2021: 119 institutionsQ1 2022: 125 institutionsQ2 2022: 113 institutionsQ3 2022: 114 institutionsQ4 2022: 117 institutionsQ1 2023: 121 institutionsQ2 2023: 100 institutionsQ3 2023: 84 institutionsQ4 2023: 92 institutionsQ1 2024: 106 institutionsQ2 2024: 115 institutionsQ3 2024: 118 institutionsQ4 2024: 113 institutionsQ1 2025: 115 institutionsQ2 2025: 102 institutionsQ3 2025: 97 institutionsQ4 2025: 101 institutionsQ1 2026: 123 institutionsQ2 2026: 147 institutions
Value heldQ1 2026: $221.3M
Q1 2021: $926.8MQ2 2021: $1.21BQ3 2021: $1.54BQ4 2021: $1.15BQ1 2022: $904.8MQ2 2022: $297.2MQ3 2022: $345.9MQ4 2022: $231.4MQ1 2023: $117.5MQ2 2023: $94.1MQ3 2023: $64.5MQ4 2023: $265.6MQ1 2024: $475.6MQ2 2024: $281.3MQ3 2024: $365.9MQ4 2024: $231.8MQ1 2025: $102.6MQ2 2025: $78.2MQ3 2025: $116.6MQ4 2025: $152.5MQ1 2026: $221.3MQ2 2026: $547.6M
Institutions holding CCCC and their total value by quarter
QuarterHoldersValue
Q2 2026147$547.6M
Q1 2026123$221.3M
Q4 2025101$152.5M
Q3 202597$116.6M
Q2 2025102$78.2M
Q1 2025115$102.6M
Q4 2024113$231.8M
Q3 2024118$365.9M
Q2 2024115$281.3M
Q1 2024106$475.6M
Q4 202392$265.6M
Q3 202384$64.5M
Q2 2023100$94.1M
Q1 2023121$117.5M
Q4 2022117$231.4M
Q3 2022114$345.9M
Q2 2022113$297.2M
Q1 2022125$904.8M
Q4 2021119$1.15B
Q3 2021113$1.54B
Q2 2021107$1.21B
Q1 202183$926.8M

Institutions, Q1 2026

Shares, value and share of portfolio for each institution holding C4 Therapeutics, Inc.; share changes are against Q4 2025.

Institutions holding CCCC in Q1 2026
InstitutionSharesValue% of portfolioChange in sharesAction
Wells Fargo & Company867,911$2.28M0.00%+58,651+7.2%Added
Geode Capital Management, LLC951,043$2.50M0.00%−37,835−3.8%Reduced
D. E. Shaw & Co., Inc.1,060,331$2.79M0.00%+1,007,452+1,905.2%Added
Jane Street Group, LLC1,246,896$3.28M0.00%+372,102+42.5%Added
Susquehanna International Group, LLP1,286,840$3.38M0.00%−488,943−27.5%Reduced
Millennium Management LLC1,393,342$3.66M0.00%+204,373+17.2%Added
Acadian Asset Management LLC1,890,914$4.97M0.01%+1,233,741+187.7%Added
Silverarc Capital Management, LLC1,911,785$5.03M0.59%−82,439−4.1%Reduced
BlackRock, Inc.2,048,526$5.39M0.00%+78,712+4.0%Added
Squadron Capital Management LLC2,250,000$5.92M2.37%+2,250,000New
Bank of America Corp2,359,241$6.20M0.00%−28,345−1.2%Reduced
Goldman Sachs Group Inc2,387,378$6.28M0.00%+1,298,358+119.2%Added
Renaissance Technologies LLC2,461,815$6.47M0.01%+859,235+53.6%Added
Citadel Advisors LLC2,511,015$6.60M0.00%+2,063,207+460.7%Added
JPMorgan Chase & Co3,223,054$7.57M0.00%+3,217,109+54,114.5%Added
Wasatch Advisors Inc2,961,761$7.79M0.05%−1,383,157−31.8%Reduced
Two Sigma Investments, LP3,035,634$7.98M0.01%+1,526,031+101.1%Added
Soleus Capital Management, L.P.3,803,942$10.0M0.41%00.0%Unchanged
Vanguard Capital Management LLC3,861,852$10.2M0.00%+3,861,852New
Lynx1 Capital Management LP6,998,902$18.4M2.91%−99,231−1.4%Reduced
Bain Capital Life Sciences Investors, LLC7,171,910$18.9M1.70%00.0%Unchanged
Ra Capital Management, L.P.8,000,000$21.0M0.22%00.0%Unchanged
Morgan Stanley9,072,400$23.9M0.00%+90,738+1.0%Added
Two Sigma Advisers, LP0$00.00%−1,068,200−100.0%Sold out
ArrowMark Colorado Holdings LLC0$00.00%−204,505−100.0%Sold out
Susquehanna Fundamental Investments, LLC0$00.00%−67,617−100.0%Sold out
Group One Trading, L.P.0$00.00%−38,994−100.0%Sold out
Lighthouse Investment Partners, LLC0$00.00%−33,660−100.0%Sold out
Simplex Trading, LLC0$00.00%−30,658−100.0%Sold out
Engineers Gate Manager LP0$00.00%−24,416−100.0%Sold out
Virtu Financial LLC0$00.00%−20,655−100.0%Sold out
Delta Investment Management, LLC0$00.00%−20,000−100.0%Sold out
R Squared Ltd0$00.00%−13,674−100.0%Sold out
Optima Capital LLC0$00.00%−226−100.0%Sold out
Vanguard Group Inc––––Not filed